E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
Idiopathic generalized epilepsy |
Epilepsia idiopatica generalizada |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10071096 |
E.1.2 | Term | Idiopathic generalized epilepsy |
E.1.2 | System Organ Class | 100000004852 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the efficacy of oral lacosamide (LCM) vs placebo as adjunctive therapy for uncontrolled primary generalized tonic-clonic (PGTC) seizures in subjects with idiopathic generalized epilepsy (IGE) currently taking 1 to 3 concomitant anti-epileptic drugs (AEDs) independent of the number of prior failed AEDs |
Demostrar la eficacia de lacosamida oral ( LCM) frente a placebo como tratamiento complementario para las crisis generalizadas toniclonicas (TCGP) no controladas en pacientes con epilepsia idiopatica generalizada (EIG) actualmente tratados con 1 a 3 fármacos antiepilepticos (FAE) concomitantes independientemente del número de fracasos previos de FAEs. |
|
E.2.2 | Secondary objectives of the trial |
To assess the safety and tolerability of lacosamide (LCM) in subjects with idiopathic generalized epilepsy (IGE) with uncontrolled primary generalized tonic-clonic (PGTC) seizures |
Evaluar la seguridad y la tolerabilidad de lacosamida (LCM) en pacientes con epilepsia idiopatica generalizada (EIG) y crisis tonicoclonicas generalizadas primasrias (TCGP) no controladas |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
? Subject with a confirmed diagnosis at least 24 weeks prior to Visit 1 and a disease onset prior to 30 years of age, consistent with idiopathic generalized epilepsy (IGE) experiencing primary generalized tonic-clonic (PGTC) seizures (Type IIE) that are classifiable according to the International League Against Epilepsy (ILAE) Classification of Epileptic Seizures (ILAE, 1981).
? Subject has >=3 PGTC seizures during the 16-week Combined Baseline (12-week Historical Baseline plus 4-week Prospective Baseline)
? If a brain magnetic resonance imaging (MRI)/computed tomography (CT) scan has been performed, there must be no evidence of any progressive abnormality or any lesion likely to be associated with partial-onset seizures.
? Subject has been maintained on a stable dose regimen of 1 to 2 non-benzodiazepine marketed Anti-epileptic drugs (AEDs) OR 1 to 3 AEDs (with at least 1 AED identified as a benzodiazepine) for at least 28 days prior to Visit 1 with or without additional concurrent stable Vagus nerve stimulation (VNS).
? Subjects are required to have had an electroencephalogram (EEG) report consistent with IGE (eg, generalized >= 3Hz epileptiform discharges and a normal EEG background) confirmed by a Central Reviewer. |
?Paciente con un diagnóstico confirmado al menos 24 semanas antes de la Visita 1 y aparición de la enfermedad antes de los 30 años de edad, compatible con EIG con crisis TCGP (Tipo IIE) que pueden clasificarse de acuerdo a la Clasificación de las crisis epilépticas de ILAE (ILAE, 1981). ?Paciente que tiene >= 3 crisis TCGP durante el periodo combinado inicial de 16 semanas (histórico inicial de 12 semanas más prospectivo inicial de 4 semanas) ?Si se ha realizado una exploración cerebral por resonancia magnética (RM)/tomografía computerizada (TAC), no debe haber ninguna evidencia de anomalías progresivas o de ninguna lesión que pueda asociarse con crisis parciales. ?Paciente que se ha mantenido en una pauta posológica estable de 1 a 2 FAE no benzodiacepínicos comercializados O BIEN de 1 a 3 FAE (con al menos 1 FAE identificado como una benzodiacepina) durante al menos 28 días antes de la Visita 1 con o sin ENV estable concurrente adicional. ? Se requiere que los pacientes hayan obtenido un informe de EEG compatible con EIG (por ejemplo, descargas epileptiformes >= 3 Hz generalizadas y un fondo normal de EEG) confirmado por un revisor central |
|
E.4 | Principal exclusion criteria |
? History of partial onset seizures or EEG findings indicating partial onset seizures
? Symptomatic generalized epilepsy, e.g. Lennox-Gastaut Syndrome
? Lifetime history of suicide attempt, or suicidal ideation in past 6 months
? Women of child bearing potential must practice contraception according to protocol requirements
? Regular use of neuroleptics, narcotics, monoamine oxidase (MOA) inhibitors, barbiturates (for indication other than epilepsy) within 28 days prior to Visit 1
? Use of Felbamate or Vigabatrin within last 6 months
? Subject is on a ketogenic diet |
?Antecedentes de crisis parciales o hallazgos de EEG indicativos de crisis parciales. ?Epilepsia generalizada sintomática por ejemplo, el síndrome de Lennox-Gastaut. ?Antecedentes de intentos de suicidio, o idea de suicidio en los últimos seis meses. ?Las mujeres en edad fertil deben poner en practivo un metodo anticonceptivo de acuerdo a los requisitos del protocolo. ?Uso regular de neurolepticos, narcoticos, inhibidores de la monoamino oxidasa (MAO), barbituricos (para otra indicación distinta a la epilepsiaI en los 28 días previos a la visita 1 ?Uso de felbamato o Vigabatrin en los últimos seis meses. ?El paciente sigue una dieta cetógena. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Time to the second primary generalized tonic clonic (PGTC) seizure |
el tiempo hasta la segunda crisis tonicoclonica generalizada primaria (TCGP) |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
24-week Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24) |
Periodo de Tratamiento de 24 semanas desde la Visita 2 (Semana 0) a la Visita 10 (semana 24) |
|
E.5.2 | Secondary end point(s) |
Seizure freedom for primary generalized tonic clonic (PGTC) seizures
The percent change in primary generalized tonic clonic (PGTC) seizure frequency per 28 days
Time to the first primary generalized tonic clonic (PGTC) seizure |
Ausencia de crisis para las crisis tonicoclonica generalizada primaria (TCGP)
El porcentaje de cambio en la frecuencia de crisis tonicoclonica generalizada primaria (TCGP) por cada 28 días
Tiempo hasta la primera crisis tonicoclonica generalizada primaria (TCGP) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
24-week Treatment Period from Visit 2 (Week 0) to Visit 10 (Week 24)
From the Combined Baseline (combined 12-week Historical and 4-week Prospective Baseline) to the first 6 weeks of the Treatment Period |
Periodo de Tratamiento de 24 semanas desde la Visita 2 (Semana 0) a la Visita 10 (semana 24)
Desde el periodo combinado inicial (histórico de 12 semanas y prospectivo inicial de 4 semanas combinados) hasta las primeras 6 semanas del período de tratamiento |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 73 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
Australia |
Belgium |
Brazil |
Bulgaria |
Czech Republic |
France |
Germany |
Hungary |
Israel |
Italy |
Japan |
Korea, Republic of |
Mexico |
Poland |
Portugal |
Romania |
Russian Federation |
Slovakia |
Spain |
Taiwan |
Turkey |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
LVLS |
Ultima Visita del último paciente |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 14 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 6 |
E.8.9.2 | In all countries concerned by the trial days | 14 |